Zivo Bioscience to Present at Two Upcoming August Conferences
August 11 2021 - 8:00AM
Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D
company engaged in the development and commercialization of
therapeutic, medicinal and nutritional product candidates
originally derived from proprietary algal cultures, today announced
that President and CEO Andrew Dahl is scheduled to present at the
following virtual conferences:
Q3 Investor Summit: August 17 – 18, 2021
Mr. Dahl will deliver his corporate presentation on August 17 at
9:30 am ET.
Management will be available for one-on-one meetings throughout
the conference.
Investors can register here: Q3 Investor Summit Investor
Registration
SNN Network Summer Virtual Event Investor Conference:
August 17 – 19, 2021
Mr. Dahl will deliver his corporate presentation on August 19 at
9:30 am ET.
Management will be available for one-on-one meetings to be held
throughout the conference.
Investors can register here: REGISTER
About Zivo Bioscience, Inc.
Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a
Michigan-based biotech/agtech company engaged in the investigation
of the health and nutritional benefits of bioactive compounds
derived from its proprietary algal cultures, and the development of
natural bioactive compounds for use as dietary supplements and food
ingredients, as well as biologically derived and synthetic
candidates for medicinal and pharmaceutical applications in humans
and animals, specifically focused on the general benefits of
autoimmune and inflammatory response modulation. Visit
zivobioscience.com to learn more.
Forward Looking Statements
Except for any historical information, the
matters discussed in this press release contain forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Although ZIVO believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our strategic partnerships may not facilitate
the commercialization or market acceptance of our products; risks
that our products may not be ready for commercialization in a
timely manner or at all; risks that our products will not perform
as expected based on results of our pre-clinical and clinical
trials; our ability to raise additional funds; uncertainties
inherent in the development process of our products; changes in
regulatory requirements or decisions of regulatory authorities; the
size and growth potential of the markets for our products; the
results of clinical trials, our ability to protect our intellectual
property rights and other risks, uncertainties and assumptions,
including those described under the heading “Risk Factors” in our
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release and ZIVO undertakes no obligation to revise or update any
forward-looking statements for any reason, even if new information
becomes available in the future.
Contact:
Investor RelationsCORE
IR516-222-2560Investor@zivobioscience.com
MediaCORE IRJules
Abraham917-885-7378julesa@coreir.com
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zivo Bioscience (NASDAQ:ZIVO)
Historical Stock Chart
From Sep 2023 to Sep 2024